A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism

PHASE2CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

June 6, 2017

Primary Completion Date

December 19, 2019

Study Completion Date

December 19, 2019

Conditions
Acute Pulmonary Embolism
Interventions
DRUG

Recombinant Human Prourokinase

The drug is used for intravenous thrombolysis therapy

DRUG

Alteplase

The drug is used for intravenous thrombolysis therapy

Trial Locations (18)

100037

Fuwai Hospital, Beijing

Unknown

Anzhen Hospital, Capital Medical University, Beijing

Beijing Tongren Hospital,Capital Medical University, Beijing

The Second Affiliated Hospital of Harbin Medical University, Harbin

Henan Provincial People's Hospital, Zhengzhou

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

Wuhan Asia Heart Hospital, Wuhan

Xiangya Hospital, Central South University, Changsha

Jiangsu Province Hospital, Nanjing

Nanjing First Hospital, Nanjing

The First Affiliated Hospital of Nanchang University, Nanchang

The First Hospital of Jilin University, Changchun

The First Hospital of China Medical University, Shenyang

General Hospital of Ningxia Medical University, Yinchuan

The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an

West China Hospital of Sichuan University, Chengdu

Tianjin Chest Hospital, Tianjin

Sir Run Run Shaw Hospital affiliated with the Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Tasly Biopharmaceuticals Co., Ltd.

INDUSTRY

NCT03108833 - A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism | Biotech Hunter | Biotech Hunter